Company
Prevail Therapeutics
Advancing gene therapy
Also known as Prevail Therapeutics Inc.
- Status
- Acquiredas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Legal name
- Prevail Therapeutics Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
At Prevail, we are developing gene therapies designed to slow or stop the underlying causes of neurodegenerative and rare diseases
Funding snapshot
- Total raised
- $57MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $57M2018-03-07
Funding rounds
- Round, 2018
- $57M2018-03-07, SEC form D sold, 15 investors
About the company
- Status notes
- Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company
Loading relationship preview